Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field May 31, 2023
KSQ Therapeutics And Takeda Expand Strategic Immuno-Oncology Collaboration To Identify And Validate Novel Tumor Targets May 31, 2023
Gilead Strengthens Early Pipeline In Oncology And Inflammation Through The Acquisition Of XinThera May 18, 2023
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology May 18, 2023
Alligator Bioscience and Orion Corporation announce exercise of development option under their 2021 Immuno-oncology Research Collaboration and License Agreement May 18, 2023
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Gen ADC Program in Oncology May 10, 2023
Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics May 10, 2023
Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors May 10, 2023
First Patient Dosed in Ph 1/2 Trial of STX-478 for the Treatment of Breast Cancer and Other Solid Tumors May 10, 2023
Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME announced May 10, 2023
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients April 27, 2023
CTRL Therapeutics Launches with $10M Seed Financing to Advance Next-Gen Cell Therapy Platform for the Treatment of Solid Tumors April 20, 2023
Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets April 12, 2023
Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications April 12, 2023
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates April 6, 2023
First Patient Dosed in Ph 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors April 6, 2023
Positive Topline Data from BDC-1001 Ph 1 Dose-Escalation Trial in HER2-Expressing Tumors announced, Supporting Advancement to Ph 2 Clinical Studies April 6, 2023
FDA Converts to Full Approval Indication for KEYTRUDA® for Certain Adult and Pediatric Patients With Advanced MSI-H or dMMR Solid Tumors April 6, 2023
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights March 31, 2023
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications March 31, 2023
